Monopar Therapeutics (MNPR) EBT (2017 - 2025)
Monopar Therapeutics (MNPR) reported EBT of -$4.3 million for Q3 2025, down 189.36% on a YoY basis from $4.8 million in Q3 2024, and down 65.64% sequentially from -$2.6 million in Q2 2025.
Monopar Therapeutics (MNPR) EBT (2017 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 9 years of EBT data on file, last reported at -$4.3 million in Q3 2025.
- For the quarter ending Q3 2025, EBT fell 189.36% year-over-year to -$4.3 million; the trailing twelve-month figure through Sep 2025 stood at -$11.5 million (down 66.83% YoY), and the FY2025 full-year result was -$13.7 million, up 11.45% from the prior year.
- EBT declined to -$4.3 million in Q3 2025, from -$2.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$1.5 million in Q3 2024 to a low of -$13.4 million in Q4 2022.
- A 5-year average of -$3.5 million and a median of -$2.5 million in 2021 frame the typical range for EBT.
- Across the five-year window, EBT surged 31.6% in 2024 and sank 189.36% in 2025, its largest moves.
- Tracing MNPR's EBT over 5 years: stood at -$10.4 million in 2021, then fell by 29.03% to -$13.4 million in 2022, then soared by 85.44% to -$2.0 million in 2023, then gained by 24.47% to -$1.5 million in 2024, then slumped by 189.36% to -$4.3 million in 2025.
- Business Quant data shows MNPR's EBT at -$4.3 million in Q3 2025, -$2.6 million in Q2 2025, and -$3.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -2.58 Mn |
| Mar 31, 2025 | -3.22 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.35 Mn |
| Mar 31, 2023 | -2.49 Mn |
| Dec 31, 2022 | -13.42 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.85 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -7.48 Mn |
| Sep 30, 2020 | -1.65 Mn |
| Jun 30, 2020 | -1.46 Mn |